CRA living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs

This Canadian Rheumatology Association (CRA) guideline provides contemporary recommendations for the pharmacological management of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drug (DMARD) therapy. Recommendations are developed using the GRADE approach with a multidisciplinary panel composed of rheumatologists, researchers, methodologists, and patients, and incorporate a health equity framework developed for the Canadian RA population. Recommendations are added and updated in a living fashion over time...